3 days ago · Genesis and Incyte have agreed to collaborate on two initial targets, and Incyte will have the option to nominate an additional target for a predetermined fee. If all milestones are achieved, Genesis is eligible to receive up to $295 million in development, regulatory and commercial milestone payments per target. ...

3 days ago · Genesis and Incyte have agreed to collaborate on two initial targets, and Incyte will have the option to nominate an additional target for a predetermined fee. If all milestones are achieved ...

3 days ago · Genesis and Incyte have agreed to collaborate on two initial targets, and Incyte will have the option to nominate an additional target for a predetermined fee. If all milestones are achieved, Genesis is eligible to receive up to $295 million in development, regulatory and commercial milestone payments per target. ...

4 days ago · Genesis and Incyte have agreed to collaborate on two initial targets, and Incyte will have the option to nominate an additional target for a predetermined fee. If all milestones are achieved ...

3 days ago · Incyte has agreed to pay Genesis $30 million upfront, plus up to $295 million in payments per target—up to $590 million for the two initial targets—tied to achieving development, regulatory ...

4 days ago · Incyte and Genesis Therapeutics announced that the companies have entered into a strategic collaboration focused on the research, discovery and development of novel small molecule medicines, with ...

3 days ago · Incyte is sticking to its strategy this year of finding “early-stage, exotic stuff”—paying Genesis Therapeutics $30 million upfront to use the biotech’s artificial intelligence platform to ...

3 days ago · Genesis will receive an upfront payment of $30M and will work with Incyte on two initial drug targets, while Incyte retains the option to nominate a third target for an agreed-upon fee.

4 days ago · Incyte is making a hefty bet on AI-based drug discovery, teaming up with biotech startup Genesis Therapeutics in a deal that could be worth a total of over $900 million. The goal? To use Genesis' AI platform to design new small-molecule drugs faster and more effectively.

Incyte Corp (INCY, Financial) has announced a strategic collaboration with Genesis Therapeutics, Inc., focusing on the research, discovery, and development of novel small molecule medicines. The partnership will leverage Genesis' AI platform, GEMS, to accelerate the discovery and optimization of small molecule compounds.